TriangleRelacorilant 150 mg once daily (QD) (NCT06906341)
Relacorilant 150 mg once daily (QD) trial for Ovarian Cancer (NCT06906341). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult women with ovarian, fallopian-tube, or peritoneal cancer after one to three systemic lines: platinum-resistant, or platinum-sensitive with progression on a PARP inhibitor. An endometrial cohort requires advanced or recurrent disease after platinum and checkpoint therapy, with one to two prior lines.
The idea: relacorilant blocks glucocorticoid signaling that can support tumor growth. Oral doses surround nab-paclitaxel infusions. Ovarian cohorts also receive bevacizumab; endometrial patients do not. Researchers measure progression and safety.
This phase 2 study plans 270 patients. Corcept Therapeutics sponsors; sixteen US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.